Pancreatic Cancer Survival Advances Through New Drugs and Vaccines
Similar Articles
Gleevec, a Cancer Drug Developed Through Clinical Trials, Continues to Save Lives Decades After Approval
AI Model Detects Pancreatic Cancer Years Earlier on Routine CT Scans
Immunotherapy Shows Promise as Pre-Surgery Treatment for Specific Bowel Cancer
Pre-Surgery Immunotherapy Shows Promise for a Subtype of Colorectal Cancer
Friendship and Fundraising Provide Support for Woman Battling Cancer
New genetically engineered drugs and personalized mRNA vaccines are showing promise in improving survival for pancreatic cancer, a disease where most patients are diagnosed at a late stage. Vicky Stinson, a 65-year-old retired landscape architect, participated in a clinical trial for the drug daraxonrasib, which significantly delayed disease progression. While challenges remain, these advances are part of a broader improvement in cancer survival rates driven by immunotherapies, genetics, and AI.
Facts First
- New drug daraxonrasib delayed cancer progression to 8-9 months in trials, compared to 2-3 months for chemotherapy.
- Personalized mRNA vaccines activated an immune response in half of a small German trial group and extended life for most by about six years.
- Pancreatic cancer is often diagnosed late, with about 80% of cases found at an advanced stage and a five-year survival rate of 13%.
- Vicky Stinson participated in the daraxonrasib trial for 13 months before her cancer returned, leading to a Stage IV diagnosis and a return to chemotherapy.
- The FDA has allowed expanded access to daraxonrasib for patients and recently approved a device that uses electrical signals to treat tumors.
What Happened
Clinical trial data for the drug daraxonrasib was published in The New England Journal of Medicine last week. In the trials, the drug enabled patients to live an average of 8 to 9 months without disease progression, compared to 2-3 months for chemotherapy. Daraxonrasib is a RAS inhibitor, a class of genetically engineered medicines that target cells with certain cancerous mutations. Vicky Stinson, a 65-year-old retired landscape architect, participated in this trial for 13 months. Separately, a study in Germany showed that individualized mRNA vaccines extended life for most by approximately 6 years.
Why this Matters to You
Pancreatic cancer is diagnosed in approximately 70,000 Americans annually, and about 80% of those diagnoses occur at a late stage. The five-year survival rate is 13%. New treatments like daraxonrasib and mRNA vaccines represent tangible progress that may offer more time and better outcomes for future patients. The FDA's allowance of expanded access to daraxonrasib prior to full approval means these treatments could reach patients sooner. Advances in immunotherapies, genetics, and AI imaging have already increased the overall five-year cancer survival rate to 70%, suggesting this progress may continue.
What's Next
Stinson's cancer returned in late March, resulting in a Stage IV diagnosis in her ovaries, and she has since restarted chemotherapy. The future for new treatments appears promising but involves managing expectations. In the daraxonrasib study, approximately one-third of patients experienced moderate to severe side effects. The continued development of targeted drugs, vaccines, and devices like the recently FDA-approved 'tumor treating fields' device suggests a multi-pronged approach to treating this difficult cancer is likely to evolve.